



June 2, 2021

The Manger - Listing

BSE Limited

Corporate Relationship Dept., 1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

National Stock Exchange of India Ltd.

Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Disclosure of Related Party Transactions

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2021 for your information and records.

For **AstraZeneca Pharma India limited**

Pratap Rudra

Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628

AstraZeneca Pharma India Limited**Disclosure of related party transactions for the half year ended 31 March, 2021****In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018**

(All amounts in Rs.million)

(i) Names of related parties and related party relationship**(a) Related parties where control exists and/or where transactions have occurred:**

Name of the entity	Name of relationship
Holding Company	AstraZeneca Pharmaceuticals AB, Sweden
Holding Company of AstraZeneca Pharmaceuticals AB, Sweden	AstraZeneca AB, Sweden
Holding Company of AstraZeneca AB, Sweden	AstraZeneca Treasury Limited, United Kingdom
Ultimate Holding Company	AstraZeneca Plc, United Kingdom
Fellow subsidiaries with whom the company had transactions during the year	AstraZeneca Singapore Pte Ltd, Singapore AstraZeneca Pharmaceuticals LP, USA AstraZeneca UK Limited, United Kingdom P.T. AstraZeneca Indonesia AstraZeneca Pty Ltd, Australia AstraZeneca SDN Bhd, Malaysia
Employees' Benefit Plans	AstraZeneca Pharma India Limited Employees Gratuity Fund Trust AstraZeneca Pharma India Limited Management Staff Provident Fund Trust AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust

b) Key Management Personnel

- Managing Director	Mr. Gagandeep Singh Bedi
- Director and Chief Financial Officer	Mr. Rajesh Marwaha
- Non-Executive Directors	Mr. Ian John Parish (upto 18 May, 2020) Mr. Ankush Nandra (w.e.f. 18 May, 2020) Ms. Weiyang Sarah Wang

c) Independent Directors

Mr. Narayan K Seshadri
Ms. Revathy Ashok
Ms. Kimsuka Narasimhan

(ii) Details of the transactions with the related parties during the period 01 October 2020 to 31 March 2021 :

Purchase of raw materials and traded goods	
AstraZeneca UK Limited, United Kingdom	876.3
AstraZeneca AB, Sweden	18.3
Payment towards reimbursement of expenses	
AstraZeneca Pty Ltd, Australia	6.6

AstraZeneca Pharma India Limited**Disclosure of related party transactions for the half year ended 31 March, 2021****In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018**

(All amounts in Rs.million)

Sale of services	
AstraZeneca AB, Sweden	91.6
Recovery of reimbursable expenses	
AstraZeneca UK Limited, United Kingdom	44.6
AstraZeneca AB, Sweden	10.7
AstraZeneca Singapore Pte Ltd, Singapore	13.6
AstraZeneca Pharmaceuticals LP, USA	66.8
AstraZeneca SDN Bhd, Malaysia	4.4
Contribution to Trusts	
AstraZeneca Pharma India Limited Employees Gratuity Fund Trust	90.0
AstraZeneca Pharma India Limited Management Staff Provident Fund Trust	68.7
AstraZeneca Pharma India Limited Management Staff Superannuation Fund Trust	6.5
(iii) (a) Transactions with Key Management Personnel	
Salary and perquisites	
Short-term employee benefits	25.6
Long-term employee benefits	8.4
Post employment benefits	19.0
Employee share compensation expenses	2.8
	55.8
(iii) (b) Transactions with Independent Directors	
Sitting fees paid to independent directors	1.9

AstraZeneca Pharma India Limited

Disclosure of related party transactions for the half year ended 31 March, 2021

In pursuance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018

(All amounts in Rs.million)

(iv) **Details of balances receivable from and payable to related parties as at 31, March 2021 are as follows:**

Other current financial assets	42.1
AstraZeneca UK Limited, United Kingdom	27.1
AstraZeneca Pharmaceuticals LP, USA	5.0
AstraZeneca Singapore Pte Ltd, Singapore	7.2
AstraZeneca SDN Bhd, Malaysia	2.8
Trade receivables	85.1
AstraZeneca AB, Sweden	85.1
Trade payables	414.4
AstraZeneca UK Limited, United Kingdom	361.7
AstraZeneca AB, Sweden	49.0
AstraZeneca Pty Ltd, Australia	3.7